April 12, 2022
Dirix L et al. Breast Cancer Research and Treatments, 2022
Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
You might also be interested by
Posters
Fit-for-purpose validation and inter-laboratory cross-validation of a TBNK flow cytometry assay with improved B cell monitoring capabilities
April 14, 2026
More infoPosters
Understanding Protein Normalization: A Case Study in PBMC Fit-for-Purpose Validation by MS
April 14, 2026
More infoCellTalk Blog
Rescuing a Pilot Study: How a Coordinated Response From CellCarta Kept a Critical Program on Track
April 14, 2026
More info